Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-masked comparison of 0.5% STN1011402 ophthalmic cream in allergic conjunctivitis
jRCT2031220074Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic conjunctivitis (AC) comparing 0.5% STN1011402 ophthalmic cream with Placebo ophthalmic cream (2 arms). Primary endpoints: Efficacy (Subjective Ocular Symptom Score), Efficacy (Objective Findings Score) and 1 more. Started Jun 2022; status: completed.
02
Drugs
epinastine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on jRCT2031220074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220074.